DSM-Firmenich names Noviwest and Panavora for DSM-Firmenich stock investors

Published on 10/23/2026 at 09:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DSM-Firmenich will form Noviwest and Panavora while retaining 20.00 percent. DSM-Firmenich stock costs EUR 108.38 on October 23, 2026.

Animal nutrition separation advances

DSM-Firmenich announced Noviwest and Panavora on October 22, 2026, while retaining 20.00 percent in each company.
First-half 2026 revenue reached EUR 4.664 billion, with adjusted EBITDA margin at 19.30 percent.
DSM-Firmenich stock trades at EUR 108.38 at 9:33 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.49 percent above the Xetra close of October 22, 2026.
Third-quarter 2026 sales are scheduled for November 4, 2026.

Isometrische 3D-Grafik der Wertschöpfungskette von Rohstoff bis Vertrieb — dsm-firmenich AG (ISIN CH1216478797) veranschaulicht ihre Wertschöpfungskette von Rohstoffen bis Vertrieb als isometrische 3D-Grafik, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) announced Noviwest and Panavora on October 22, 2026, naming the two standalone companies planned for its Animal Nutrition and Health business. According to DSM-Firmenich, the transaction with CVC Capital Partners remains subject to regulatory approvals and employee consultation, while DSM-Firmenich will retain a 20.00 percent equity interest in each company.

Separation follows the divestment

The announcement gives the planned sale a clearer operating structure. Noviwest will concentrate on essential ingredients, while Panavora will focus on animal nutrition and health, including feed additives and digital services, according to the October 22 release.

The chronology shows the transaction taking shape over three dates. On February 9, 2026, DSM-Firmenich announced the sale to CVC at an enterprise value of EUR 2.2 billion, as SeafoodSource reported. On July 30, 2026, the company reported first-half revenue of EUR 4.664 billion and an adjusted EBITDA margin of 19.30 percent, according to the Yahoo Finance transcript. The October 22 naming announcement is the latest step and includes the 20.00 percent retained interest.

What comes next for sales?

The next dated corporate milestone is third-quarter 2026 sales on November 4, 2026, followed by annual 2026 results on February 18, 2027, according to the published financial calendar from Ideal Investisseur. The calendar matters because the next sales update will provide the first operating check after the separation plan became more concrete.

Stock holds above the Xetra close

DSM-Firmenich stock was trading at EUR 108.38 at Lang & Schwarz on October 23, 2026 at 9:33 a.m. CEST, up 0.49 percent versus the Xetra close of October 22, 2026 at EUR 107.85. The company had a market capitalization of EUR 27.1 billion as of October 22, 2026, while its first-half revenue was EUR 4.664 billion.

The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.